N- (3- (2- amino- 4a,5,7,7a- tetrahydro- 4H- furo(3,4- d)(1,3)thiazin- 7a- yl)- 4- fluorophenyl)- 5- fluoropicolinamide

a BACE1 inhibitor

Also Known As:

LY2886721

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Insulin Resistance 01/01/2021 - "Furthermore, LY2886721 improved hepatic insulin sensitivity, as indicated by enhanced basal hyperphosphorylation of insulin receptors. " 01/01/2021 - "Hence, we here investigated if targeted BACE1 inhibition using LY2886721, an active site BACE1 inhibitor, would improve glucose homeostasis, insulin sensitivity and motor performance in PLB4 mice. "